Chemotherapy of advanced soft‐tissue sarcomas

Antman, Karen H.; Elias, Anthony

doi:10.1002/ssu.2980040111

Cited by 26 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Doxorubicin remains the most active drug in the treatment of soft tissue sarcoma with a response rate of 10–25% in previously untreated patients [2]. Other active drugs or combinations include ifosfamide [3], gemcitabine with or without docetaxel [4, 5], and dacarbazine (DTIC) [6]. Treatment options are therefore limited and responses are often of short duration.…”

Section: Introductionmentioning

confidence: 99%

A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft‐Tissue Sarcomas

Андерсон

Keohan

D’Adamo

et al. 2006

Sarcoma

View full text Add to dashboard Cite

Introduction. The role of vinorelbine in specific soft tissue sarcoma subtypes is unclear. We present retrospective single institution experience with single-agent vinorelbine in subjects with metastatic soft tissue malignancies. Methods. Fifty-eight patients were treated with single agent intravenous vinorelbine between April 1997 and December 2004. Doxorubicin had been administered previously to 53 subjects (91%), and the median number of lines of previous chemotherapy was 3 (range 0–7). Results. Patients received a median 6 doses of vinorelbine (range 1–65). The overall response rate was 6% (3 patients: 1 angiosarcoma, 1 epithelioid sarcoma, and 1 embryonal rhabdomyosarcoma). Fourteen patients (26%) experienced a best result of stable disease. Median time to progression was 1.8 months (95% confidence intervals 1.5–2.1 months, Kaplan-Meier estimate). Eight patients experienced grade 3 or 4 toxicity, most commonly febrile neutropenia. Conclusion. Vinorelbine demonstrates limited activity in a heavily pretreated group of soft-tissue sarcoma patients. Prospective investigation may be considered for selected sarcoma subtypes.

show abstract

Section: Introductionmentioning

confidence: 99%

A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft‐Tissue Sarcomas

Андерсон

Keohan

D’Adamo

et al. 2006

Sarcoma

View full text Add to dashboard Cite

show abstract

“…Quimioterapia adjuvante no tratamento dos sarcomas é bastante controversa e para alguns autores diminuiria as taxas de controle da doença (17,18) . Em nosso estudo, a quimioterapia foi utilizada em pacientes com margens positivas, fator este de pior prognóstico, e seus resultados foram desanimadores.…”

Section: Discussionunclassified

Tratamento radioterápico adjuvante nos sarcomas de extremidades de alto grau

et al. 2010

View full text Add to dashboard Cite

OBJETIVO: Avaliar as terapias utilizadas em nossa instituição no tratamento dos sarcomas de extremidades de alto grau, mediante análise da sobrevida global do tratamento multidisciplinar. MATERIAIS E MÉTODOS: Estudo retrospectivo com 36 pacientes, no período de 1993 a 2007, em estádios IIb/III, submetidos a radioterapia externa após cirurgia com ou sem reforço de dose com braquiterapia. RESULTADOS: Trinta e seis pacientes foram submetidos a tratamento cirúrgico seguido de radioterapia externa, sendo que quatro pacientes (11%) receberam reforço de dose com braquiterapia e sete pacientes (19%) receberam quimioterapia. A dose mediana de radioterapia foi de 50 Gy (IC95%: 47-53 Gy), sendo realizado reforço de dose em quatro pacientes com braquiterapia, com dose variando de 16,2-35 Gy. A quimioterapia foi indicada em sete pacientes (19%) com margens positivas. Quinze pacientes apresentaram recidiva local e/ou a distância (42%) e todos faleceram. Vinte e um pacientes (58%) encontram-se sem evidência clínica e radiológica de recidiva local e/ou a distância. O seguimento mediano é de 88 meses (IC95%: 74-102). A taxa de sobrevida global para sete anos foi de 80%. CONCLUSÃO: Concluímos que a associação cirurgia + radioterapia apresenta-se como tratamento eficaz e com ótimas respostas e melhora da sobrevida global na possibilidade de associação da braquiterapia.

show abstract

“…The genital sarcoma of uterus, vulva, vagina, or ovary has a very low incidence and is usually an aggressive disease with very heterogeneous tumor histology. Additional to limited therapeutic options, especially with respect to systemic therapy, the prognosis substantially depends on the extent of the tumor at time of diagnosis …”

Section: Preclinical and Clinical Research On Women's Healthmentioning

confidence: 99%

Organ‐on‐a‐Chip Systems for Women's Health Applications

Nawroth

Rogal

Weiß

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Biomedical research, for a long time, has paid little attention to the influence of sex in many areas of study, ranging from molecular and cellular biology to animal models and clinical studies on human subjects. Many studies solely rely on male cells/tissues/animals/humans, although there are profound differences in male and female physiology, which can significantly impact disease mechanisms, toxicity of compounds, and efficacy of pharmaceuticals. In vitro systems have been traditionally very limited in their capacity to recapitulate female-specific physiology and anatomy such as dynamic sex-hormone levels and the complex interdependencies of female reproductive tract organs. However, the advent of microphysiological organ-on-a-chip systems, which attempt to recreate the 3D structure and function of human organs, now gives researchers the opportunity to integrate cells and tissues from a variety of individuals. Moreover, adding a dynamic flow environment allows mimicking endocrine signaling during the menstrual cycle and pregnancy, as well as providing a controlled microfluidic environment for pharmacokinetic modeling. This review gives an introduction into preclinical and clinical research on women's health and discusses where organ-on-a-chip systems are already utilized or have the potential to deliver new insights and enable entirely new types of studies.

show abstract

Chemotherapy of advanced soft‐tissue sarcomas

Cited by 26 publications

References 30 publications

A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft‐Tissue Sarcomas

A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft‐Tissue Sarcomas

Tratamento radioterápico adjuvante nos sarcomas de extremidades de alto grau

Organ‐on‐a‐Chip Systems for Women's Health Applications

Contact Info

Product

Resources

About